Thrombolytic drugs activate plasminogen which creates a cleaved form called plasmin, a
proteolytic enzyme that breaks the crosslinks between fibrin molecules. The crosslinks …

Background Thromboses is a rapidly growing medical problem worldwide. Low-cost, high-
scale production of thrombotic drugs is needed to meet the demand. The production of …

The human tissue-type plasminogen activator (tPA) is a key kinase of fibrinolysis that plays
an important role in dissolving fibrin clots to promote thrombolysis. The recombinant human …

Background: Solubility of recombinant therapeutic enzymes is one of the major purpose their
production in bacterial host The factors such as metabolic system, a cellular stress response …

Background: The aim of this study was to determine the best condition for the production of
DT386-BR2 fusion protein, an immunotoxin consisting of catalytic and translocation domains …

Biosynthesis of very long chain polyunsaturated fatty acids (VLCPUFA) such as
docosahexaenoic acid (DHA, 22: 6-4, 7, 10, 13, 16, 19) and docosapentaenoic acid (DPA …

Background: Reteplase is a nonglycosylated derivative of recombinant tissue plasminogen
activator, a thrombolytic agent, which can be easily expressed in Escherichia coli. However …

Background: Reteplase, the recombinant form of tissue plasminogen activator, is a
thrombolytic drug with outstanding characteristics, while demonstrating limited solubility and …

The high-yield production of vascular endothelial growth factor (VEGF), as a major
therapeutic target in pathological angiogenesis and diabetic wound healing, provides critical …

В терапии неотложных состояний, вызванных тромбообразованием, важное место
занимает терапия тканевыми активаторами плазминогена (ТАП)[1]. На данный момент …